Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 456

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Hamuryudan, Vedat, Mat, Cem, Saip, Sebahattin, Ozyazgan, Yilmaz, Siva, Aksel, Yurdakul, Sebahattin, Zwingenberger, Kai, Yazici, Hasan · 1998 · Annals of Internal Medicine

Abstract

BACKGROUND: Recurrent oral and genital ulcers are the most frequent problem in the management of the Behçet syndrome. Uncontrolled experience suggests that thalidomide may help prevent recurrences of these ulcers. OBJECTIVE: To determine the efficacy of two thalidomide dosages in the treatment of mucocutaneous lesions of the Behçet syndrome. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Specialist outpatient clinic for the Behçet syndrome in Turkey. PATIENTS: 96 male patients with the Behçet syndrome who primarily had mucocutaneous lesions without major organ involvement. INTERVENTION: Thalidomide, 100 mg/d or 300 mg/d, or placebo for 24 weeks. MEASUREMENTS: Sustained absence of any oral and genital ulceration during treatment (complete response) and changes in the number of mucocutaneous lesions. An additional evaluation was done 4 weeks after treatment ended. RESULTS: A complete response occurred in 2 of the 32 patients (6% [95% CI, 0.8% to 20.8%]) receiving thalidomide, 100 mg/d; in 5 of the 31 patients (16% [CI, 5.5% to 33.7%]) receiving thalidomide, 300 mg/d; and in none of the 32 patients (0% [CI, 0% to 10.9%]) receiving placebo (P = 0.031). The suppressive effect of thalidomide with either dosage was evident at 4 weeks for oral ulcers (P < 0.001) and at 8 weeks for genital ulcers (P < 0.001) and follicular lesions (P = 0.008). This effect persisted during treatment but diminished rapidly after treatment was discontinued. Both thalidomide dosages led to significant increases in the number of erythema nodosum lesions during the first 8 weeks of treatment (P = 0.03). Polyneuropathy developed in 4 patients (1 in the 100-mg/d group and 3 in the 300-mg/d group); in 3 of these patients, the condition was diagnosed after the trial had ended. CONCLUSIONS: Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome. A dosage of 100 mg/d is as effective as a dosage of 300 mg/day.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-128-6-199803150-00004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 456

Metadata

Authors
Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K., & Yazici, H.
Venue
Annals of Internal Medicine
Published
1998-03-15
Volume
128
Issue
6
Pages
443-450
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2104613102
Cited by
456
References
8
FWCI
29.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-128-6-199803150-00004
The paper
Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K., & Yazici, H. (1998). Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-128-6-199803150-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.